



Bristol-Myers Squibb Company  
Patent Department

RECEIVED  
CENTRAL FAX CENTER

FEB 16 2005

FACSIMILE TRANSMITTAL SHEET

**DATE:** February 16, 2005  
**TO:** C. Aulakh, USPTO  
**FACSIMILE NO.:** 703-872-9306  
**FROM:** Laurelee A. Duncan  
**TELEPHONE NO.:** (609) 252-5323  
**FACSIMILE NO.:** (609) 252-4526  
**COMPANY:** Bristol-Myers Squibb Company  
**Number of Pages:** 58 (including cover sheet)

If you do not receive a complete fax, please contact Tina Markee.  
Telephone: (609) 252-4300.

**COMMENTS:**

U.S. S.N. 10/621,909; Filed: July 17, 2003

*This document contains privileged client-attorney communications. The information is intended to be for use of the addressee only. If you are not the addressee, note that any disclosure, copy, distribution or use of the contents of this document is prohibited. If you have received this message in error, please notify the sender of the error and delete the message. Thank you.*

**CONFIDENTIALITY NOTICE** - This document is intended only for the person(s) named in the message header. Unless otherwise indicated, it contains information that is confidential, privileged and/or exempt from disclosure under applicable law. If you have received this message in error, please notify the sender of the error and delete the message. Thank you.

FEB. 16: 2005 2:15PM

BMS PATENT DEPT

NO. 6824 P. 2

RECEIVED  
CENTRAL FAX CENTER

BY FACSIMILE

FEB 16 2005

CASE QA0266 NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Vaccaro, et al.

APPLICATION NO: 10/621,909

FILED: July 17, 2003

FOR: Modulators of the Glucocorticoid Receptor and Method

Art Unit: 1625

Examiner: C. Aulakh

Confirmation No. 2136

Commissioner for Patents  
Alexandria, VA 22313-1450

Amendment After Allowance (§312)

Sir:

Applicants are submitting this amendment in response to the Notice of Allowance mailed November 17, 2004, and a February 15, 2005 conversation with the Examiner.

“Amendments to the Claims” are represented by the listing of Claims which begin on page 2 of this paper. “Remarks” begin on page 56 of this paper.